首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   312695篇
  免费   20367篇
  国内免费   1155篇
耳鼻咽喉   3591篇
儿科学   9207篇
妇产科学   6256篇
基础医学   42113篇
口腔科学   10835篇
临床医学   26420篇
内科学   68117篇
皮肤病学   7054篇
神经病学   28130篇
特种医学   11079篇
外国民族医学   32篇
外科学   43184篇
综合类   3247篇
现状与发展   3篇
一般理论   196篇
预防医学   27876篇
眼科学   6240篇
药学   20417篇
中国医学   906篇
肿瘤学   19314篇
  2023年   1519篇
  2022年   1254篇
  2021年   5611篇
  2020年   4278篇
  2019年   6123篇
  2018年   8062篇
  2017年   6144篇
  2016年   6286篇
  2015年   7297篇
  2014年   10214篇
  2013年   13386篇
  2012年   20668篇
  2011年   21836篇
  2010年   11753篇
  2009年   10897篇
  2008年   18515篇
  2007年   19746篇
  2006年   18582篇
  2005年   19054篇
  2004年   17979篇
  2003年   16755篇
  2002年   14299篇
  2001年   6344篇
  2000年   5944篇
  1999年   5696篇
  1998年   3112篇
  1997年   2487篇
  1996年   2234篇
  1995年   2306篇
  1994年   2149篇
  1993年   2036篇
  1992年   3387篇
  1991年   3330篇
  1990年   2928篇
  1989年   2911篇
  1988年   2643篇
  1987年   2499篇
  1986年   2317篇
  1985年   2272篇
  1984年   1873篇
  1983年   1550篇
  1982年   1318篇
  1981年   1196篇
  1980年   1076篇
  1979年   1267篇
  1978年   964篇
  1977年   860篇
  1975年   824篇
  1974年   784篇
  1973年   757篇
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
Oral squamous cell carcinomas (OSCCs) develop in genetically altered epithelium in the mucosal lining, also coined as fields, which are mostly not visible but occasionally present as white oral leukoplakia (OL) lesions. We developed a noninvasive genetic assay using next-generation sequencing (NGS) on brushed cells to detect the presence of genetically altered fields, including those that are not macroscopically visible. The assay demonstrated high accuracy in OL patients when brush samples were compared with biopsies as gold standard. In a cohort of Fanconi anemia patients, detection of mutations in prospectively collected oral brushes predicted oral cancer also when visible abnormalities were absent. We further provide insight in the molecular landscape of OL with frequent changes of TP53, FAT1 and NOTCH1. NGS analysis of noninvasively collected samples offers a highly accurate method to detect genetically altered fields in the oral cavity, and predicts development of OSCC in high-risk individuals. Noninvasive genetic screening can be employed to screen high-risk populations for cancer and precancer, map the extension of OL lesions beyond what is visible, map the oral cavity for precancerous changes even when visible abnormalities are absent, test accuracy of promising imaging modalities, monitor interventions and determine genetic progression as well as the natural history of the disease in the human patient.  相似文献   
2.
3.
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Akteure der öffentlichen Gesundheit (Public Health) tragen wesentlich zu Gesundheitsschutz, -förderung und...  相似文献   
4.
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz -  相似文献   
5.
6.
7.
Odontology - The purpose of this study was to investigate whether the root perforation repair with mineral aggregate-based cements affects the retention of customized fiberglass posts to bovine...  相似文献   
8.
9.
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible.  相似文献   
10.
Die Anaesthesiologie - Die Anlage einer Magensonde im OP oder auf einer Intensivstation (ITS) stellt eine alltäglich durchgeführte Prozedur dar. Obwohl die Sonde häufig durch...  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号